공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

야토병 : 파이프라인 리뷰

Tularaemia (Infectious Disease) - Drugs in Development, 2021

리서치사 Global Markets Direct
발행일 2021년 09월 상품 코드 293888
페이지 정보 영문 44 Pages
가격
US $ 2,000 ₩ 2,367,000 PDF (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,735,000 PDF (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 7,102,000 PDF (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


야토병 : 파이프라인 리뷰 Tularaemia (Infectious Disease) - Drugs in Development, 2021
발행일 : 2021년 09월 페이지 정보 : 영문 44 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

야토병은 야토병균(Francisella Tularensis)으로 불리는 세균에 기인한 감염증입니다. 주로 절족동물(특히 진드기나 모기)에 물려서 감염됩니다. 피부, 결막낭, 구강점막을 통해 감염된 동물과 동물성 물질과의 직접 적촉, 오염된 먼지와 에어로졸 흡입에 의해 감염됩니다. 증상은 피부 궤양, 임파선 부종과 통증, 발열, 오한 등입니다. 치료법에는 항생물질과 건강한 라이프 스타일이 있습니다.

야토병(Tularaemia) 치료제 개발 상황에 대해 조사 분석했으며, 파이프라인 제품 개요, 임상시험 단계별 제품 개요, 주요 기업 개요, 약제 개요, 파이프라인 제품의 최신 동향, 최신 뉴스와 프레스 릴리스 등의 정보를 전해드립니다.

목차

서론

야토병 개요

치료제 개발

  • 파이프라인 제품 : 개요
  • 기업별 파이프라인
  • 대학/연구기관별 파이프라인
  • 기업에서 개발중인 제품
  • 대학/연구기관에서 개발중인 제품

치료제 평가

  • 표적별
  • 작용기서별
  • 투여 경로별
  • 분자 종류별

치료제 개발에 참여하고 있는 기업

  • Aradigm Corp
  • Arno Therapeutics Inc
  • DynPort Vaccine Company LLC
  • Emergent BioSolutions Inc
  • EpiVax Inc
  • Grifols SA
  • Merck & Co Inc
  • Tetraphase Pharmaceuticals Inc

약제 개요

휴지 상태 프로젝트

개발이 중지된 제품

제품 개발 마일스톤

  • 최신 뉴스와 프레스 릴리스

부록

도표

KSM 17.07.24

List of Tables

List of Tables

  • Number of Products under Development for Tularaemia, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Universities/Institutes, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Tularaemia - Pipeline by Appili Therapeutics Inc, 2021
  • Tularaemia - Pipeline by Aradigm Corp (Inactive), 2021
  • Tularaemia - Pipeline by DynPort Vaccine Company LLC, 2021
  • Tularaemia - Pipeline by Emergex Vaccines Holding Ltd, 2021
  • Tularaemia - Pipeline by EpiVax Inc, 2021
  • Tularaemia - Dormant Projects, 2021
  • Tularaemia - Dormant Projects, 2021 (Contd..1)
  • Tularaemia - Discontinued Products, 2021

List of Figures

List of Figures

  • Number of Products under Development for Tularaemia, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Number of Products by Top 10 Targets, 2021
  • Number of Products by Stage and Top 10 Targets, 2021
  • Number of Products by Top 10 Mechanism of Actions, 2021
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2021
  • Number of Products by Top 10 Routes of Administration, 2021
  • Number of Products by Stage and Top 10 Routes of Administration, 2021
  • Number of Products by Top 10 Molecule Types, 2021
  • Number of Products by Stage and Top 10 Molecule Types, 2021

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Tularaemia - Drugs In Development, 2021, provides an overview of the Tularaemia (Infectious Disease) pipeline landscape.Tularaemia is an infection caused due to a bacterium called Francisella tularensis. Humans become infected mainly through the bite of arthropods, particularly ticks and mosquitoes, and through the skin, conjunctival sac or oropharyngeal mucosa, by direct contact with infected animals or animal materials and by ingestion of contaminated food or water or inhalation of contaminated dust or aerosols. Symptoms include skin ulcer, swollen and painful lymph glands, fever and chills. Treatment includes antibiotics and healthy lifestyle.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Tularaemia - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Tularaemia (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Tularaemia (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Tularaemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Preclinical stages are 1 and 4 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 2 and 1 molecules, respectively.

Tularaemia (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Tularaemia (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Tularaemia (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Tularaemia (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Tularaemia (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Tularaemia (Infectious Disease)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Tularaemia (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Tularaemia (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Tularaemia - Overview
  • Tularaemia - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Tularaemia - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Tularaemia - Companies Involved in Therapeutics Development
  • Appili Therapeutics Inc
  • Aradigm Corp (Inactive)
  • DynPort Vaccine Company LLC
  • Emergex Vaccines Holding Ltd
  • EpiVax Inc
  • Tularaemia - Drug Profiles
  • ATI-1701 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ciprofloxacin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NDBR-101 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules for Infectious Diseases - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SRI-011225 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • tularaemia [strain B] vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • tularaemia vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • tularaemia vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • tularemia vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Tularaemia - Dormant Projects
  • Tularaemia - Discontinued Products
  • Tularaemia - Product Development Milestones
  • Featured News & Press Releases
  • Sep 15, 2021: MRIGlobal expert co-authors article examining effective methods for Elusive Tularemia Vaccine
  • Dec 29, 2020: VAXIL provides update on USAMRIID and oral experiments
  • Jan 28, 2020: Researchers present positive interim data on Appili Therapeutics' ATI-1701 Biodefense program at 2020 ASM Biothreats
  • Nov 18, 2019: Researchers present new positive interim data on Appili Therapeutics ATI-1701 biodefense program at 2019 Chemical and Biological Defense Science & Technology Conference
  • Aug 20, 2019: Researchers to present new data on ATI-1701 at the 2019 Military Health System Research Symposium
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
Back to Top
전화 문의
F A Q